US FDA: BD Didn't Document Faulty Lead-Test Warning
Executive Summary
An FDA-483 released as part of an ongoing probe into Magellen’s faulty LeadCare tests found potential GMP and Medical Device Reporting violations at a BD location.
You may also be interested in...
BD Handed US FDA Warning Letter In Lead-Test Investigation
The agency letter cites quality systems, Medical Device Reporting and device clearance concerns. It stems from an ongoing investigation into lead tests distributed by Magellan Biosciences that sometimes give faulty results.
US FDA: Magellan Failed To Ensure Lead Test Accuracy
A US FDA Form-483 inspection report form shows GMP, complaint handling and Medical Device Reporting violations at the Massachusetts facility of Magellan, which is facing serious scrutiny over lead test mishaps.
US FDA, CDC Warn Of False Results On Lead Blood Tests
Common blood tests for lead poisoning manufactured by Magellan Diagnostics could give false low results if used with venous blood, FDA warned. About 8 million of the tests have been performed since 2014.